AbbVie's Elahere Approved by NICE for NHS Availability
The U.K.'s National Health Service (NHS) will begin offering AbbVie’s ovarian cancer therapy, Elahere, following a recommendation from the National Institute for Health and Care Excellence (NICE). This approval is expected to expand access to the treatment in the UK.
Tickers: $ABBV
Topics: healthcare pharmaceuticals